Live Feeds
● LIVE Updated 4h ago · 8 sources tracked

Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial

Roche reported positive Phase 2 trial results for enicepatide, a GLP-1/GIP dual agonist targeting overweight patients with type 2 diabetes. Patients receiving the highest dose achieved an average weight loss of 15.5% and 90% reached a key blood sugar target after 48 weeks. Analysts describe the drug as competitive following this second mid-stage win. The treatment was originally acquired through Roche's purchase of Carmot Therapeutics.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Enicepatide is a GLP-1/GIP dual agonist.
  • ✓ Patients on the highest dose of enicepatide lost an average of 15.5% of their body weight.
  • ✓ Ninety percent of patients on the highest dose hit a key blood sugar target after 48 weeks.
  • ✓ The drug was acquired by Roche via Carmot Therapeutics.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Roche released Phase 2 data showing enicepatide delivers 15.5% weight loss and improved blood sugar control in diabetic patients.

Live updates

  1. Roche Obesity Drug Enicepatide Hits Phase 2 Targets for Diabetes and Weight Loss

    Roche reported positive Phase 2 trial results for enicepatide, a GLP-1/GIP dual agonist targeting overweight patients with type 2 diabetes. Patients receiving the highest dose achieved an average weight loss of 15.5% and 90% reached a key blood sugar target after 48 weeks. Analysts describe the drug as competitive following this second mid-stage win. The treatment was originally acquired through Roche's purchase of Carmot Therapeutics.

    Why it matters

    The obesity and type 2 diabetes markets are growing exponentially. This drug enters a crowded field of GLP-1 receptor agonists aimed at metabolic health. Success in these trials positions Roche to compete for a best-in-disease status.

    What is confirmed

    • Enicepatide is a GLP-1/GIP dual agonist.
    • Patients on the highest dose of enicepatide lost an average of 15.5% of their body weight.
    • Ninety percent of patients on the highest dose hit a key blood sugar target after 48 weeks.
    • The drug was acquired by Roche via Carmot Therapeutics.
    • The trial was a Phase 2 study involving overweight patients with diabetes.

    What to watch next

    • Results from Phase 3 clinical trials
    • Regulatory filing dates for enicepatide
    Sources used for this update (9)
    1. WSJ — Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
    2. Reuters — Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
    3. Fierce Biotech — Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
    4. Endpoints News — Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes
    5. FirstWord Pharma — Analysts say Roche's GLP-1/GIP agonist appears 'competitive' after second mid-stage win
    6. www.marketscreener.com — Viking Therapeutics Plans Offering of Common Shares, Senior Notes due 2032
    7. pharma.economictimes.indiatimes.com — Roche’s dual agonist enicepatide delivers 15.5% weight loss in type-2 diabetics
    8. www.yahoo.com — Roche obesity and diabetes drug enicepatide Phase 2 trial results
    9. www.yahoo.com — Roche’s acquired GLP-1/GIP normalises blood sugar in Phase II trial
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community